212,000 Shares in MEDNAX Inc (MD) Purchased by Ardevora Asset Management LLP

Share on StockTwits

Ardevora Asset Management LLP acquired a new position in MEDNAX Inc (NYSE:MD) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 212,000 shares of the company’s stock, valued at approximately $9,892,000.

Several other large investors have also modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of MEDNAX by 3.1% in the 2nd quarter. BlackRock Inc. now owns 8,125,250 shares of the company’s stock worth $351,662,000 after acquiring an additional 245,301 shares during the last quarter. Pzena Investment Management LLC lifted its holdings in shares of MEDNAX by 1.8% in the 2nd quarter. Pzena Investment Management LLC now owns 2,299,800 shares of the company’s stock worth $99,535,000 after acquiring an additional 41,088 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of MEDNAX by 6.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,182,992 shares of the company’s stock worth $94,481,000 after acquiring an additional 124,936 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of MEDNAX by 4.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,264,410 shares of the company’s stock worth $54,724,000 after acquiring an additional 54,120 shares during the last quarter. Finally, Wells Fargo & Company MN lifted its holdings in shares of MEDNAX by 5.1% in the 2nd quarter. Wells Fargo & Company MN now owns 886,955 shares of the company’s stock worth $38,389,000 after acquiring an additional 43,426 shares during the last quarter. 95.92% of the stock is owned by institutional investors and hedge funds.

In related news, insider John C. Pepia sold 3,500 shares of MEDNAX stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $48.18, for a total transaction of $168,630.00. Following the completion of the sale, the insider now owns 30,148 shares in the company, valued at approximately $1,452,530.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.40% of the company’s stock.

Several equities research analysts have recently issued reports on the stock. Robert W. Baird lowered their target price on shares of MEDNAX from $50.00 to $48.00 and set a “neutral” rating for the company in a report on Friday, October 19th. Leerink Swann upgraded shares of MEDNAX from a “market perform” rating to an “outperform” rating in a report on Monday, September 24th. Bank of America upgraded shares of MEDNAX from an “underperform” rating to a “neutral” rating and lowered their target price for the stock from $60.00 to $50.00 in a report on Tuesday, September 18th. Zacks Investment Research upgraded shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Tuesday, August 7th. Finally, ValuEngine upgraded shares of MEDNAX from a “strong sell” rating to a “sell” rating in a report on Friday, August 3rd. One analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $54.00.

Shares of MD opened at $41.29 on Thursday. MEDNAX Inc has a 1-year low of $40.56 and a 1-year high of $63.04. The stock has a market cap of $3.87 billion, a P/E ratio of 12.03, a P/E/G ratio of 1.14 and a beta of 0.23. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.52 and a quick ratio of 1.52.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

Recommended Story: What is the yield curve?

Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply